BioNTech SE - ADR

NASDAQ:BNTX  
108.40
+2.97 (+2.82%)
4:20:10 PM EDT: $108.25 -0.15 (-0.14%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)26.85B
Current PEN/A
Forward PE N/A
2yr Forward PE 5.38
See more stats
Estimates Current Quarter
Revenue$348.91 Million
Adjusted EPS$0.13
See more estimates
10-Day MA$104.27
50-Day MA$104.68
200-Day MA$76.13
See more pivots

BioNTech SE Stock, NASDAQ:BNTX

AN DER GOLDGRUBE 12, MAINZ, GERMANY 55131
Germany
Phone: 0049613190847081
Number of Employees:

Description

BioNTech was founded in 2008 on the understanding that every cancer patient??s tumor is unique and that in order to effectively address this challenge, we must create individualized treatments for each patient. To realize this vision, BioNTech combine decades of groundbreaking research in immunology, cutting-edge therapeutic platforms and a suite of patient profiling and bioinformatic tools to develop individualized immunotherapies for cancer as well as other diseases. We leverage powerful new therapeutic mechanisms and exploit a diverse array of biological targets to harness the power of each patient??s immune system to address the unique molecular signature of each patient??s underlying disease. We believe we are uniquely positioned to develop and commercialize the next generation of immunotherapies with the potential to significantly improve clinical outcomes for patients and usher in a new era of individualized medicine.